Epigenetic mechanisms are inheritable factors that regulate genetic expression without 76 changing the DNA sequence, and include DNA methylation, histone modification, and 77 small regulatory RNAs. DNA methylation involves modification of cytosine nucleotides 78 within the promoter region, specifically cytosines adjacent to guanosine (CpG islands) . 79
Regulation of histone acetylation/deacetylation influences chromatin structure and the 80 access to transcriptional machinery. The histone acetyltransferases and histone 81 deacetylases work in concert to tightly regulate this process. Their activity, critical for 82 normal cellular homeostasis, can be disrupted in disease states, leading to pathologic 83 gene expression. Epigenetic mechanisms contribute to the pathogenesis of diseases 84 such as cancer and atherosclerosis, which have features in common with IPAH 85 including proliferation, inflammation and vascular remodeling (40, 42) . Furthermore, 86 epigenetic mechanisms have been implicated in the regulation of the mitochondrial 87 isoform of SOD, SOD2 (2). It is therefore important to identify the epigenetic pattern in 88 these cells, which in turn can be used as an epigenetic biomarker for new and improved 89 therapeutic development. To date, there is limited information on the epigenetic 90 regulation of SOD3. We tested the hypothesis that SOD3 gene expression is silenced 91 in IPAH by epigenetic mechanisms, and thus enhances pulmonary artery smooth 92 muscle cell (PASMC) proliferation. We utilized lung tissue and PASMC provided by the 93
Pulmonary Hypertension Breakthrough Initiative (PHBI) obtained from subjects with 94
IPAH at the time of lung transplantation and failed donors to measure SOD3 gene and 95 protein expression, and to test if decreased DNA methylation and/or increased histone 96 acetylation regulate SOD3 expression. 97 98
Methods:
99
Human lung tissue and PASMC 100
Technologies) designed for human SOD3 (Hs00984230_m1), HDAC1 153 (Hs02621185_s1), HDAC2 (Hs00231032_m1), HDAC3 (Hs00187320_m1), SP1 154 (Hs00916521) and housekeeping gene β2 microglobin (β2M) (Hs00162090_m1); and 155 rat Sod3 (Rn00563570_m1) and housekeeping gene glyceraldehyde 3-phosphate 156 dehydrogenase (Gapdh) (Rn00563570_m1). 157
158

Protein preparation: 159
Cells and tissue were homogenized in 300 mM NaCl, 0.5% Triton X-100 in phosphate 160 were separated by gel electrophoresis using Criterion XT 4-12% Bis-Tris gels (Bio-Rad) 172 with MES SDS running buffer (Life Technologies). Proteins were transferred to 173 polyvinylidene fluoride membranes,(Bio-Rad) with NuPAGE transfer buffer using a 174
Novex Semi-Dry Blotter (Life Technologies). Membranes were activated in methanol 175 and blocked in 5% nonfat dry milk in Tris buffered saline containing 0.05% Tween20 176 (TBST) for 1 hour. Membranes were incubated in the following primary antibodies 177 prepared at 1:1,000 in 5% milk in TBST at 4°C, overnight unless otherwise noted: rabbit 178 polyclonal SOD3, rabbit polyclonal SOD2 (EMD Millipore, Billerica, MA), rabbit 179 polyclonal Calnexin (H-70) (Santa Cruz Biotechnology, Dallas, TX), mouse monoclonal 180 β-actin clone AC-74 (1:10,000 at room temperature for 1 hour) (Sigma-Aldrich), rabbit 181 polyclonal histone H3ac (1:1,500)(Active Motif, Carlsbad, CA) at 1:1,500, rabbit 182 polyclonal histone H4ac (Active Motif) at 1:1,000, rabbit polyclonal histone H3 183
(1:10,000)(Active Motif) at 1:10,000 , rabbit polyclonal acetyl-Lysine (Cell Signaling), 184 and rabbit polyclonal SP1 (EMD Millipore) in TBST. The appropriate horseradish 185 peroxidase conjugated anti-rabbit or mouse secondary antibody (EMD Millipore) was 186 applied at 1:10,000 in TBST for 1 hour at room temperature. To calculate the SOD activity, several dilutions of the samples were performed to find 2 205 dilutions that contained between 0.5 -2 U/ml SOD activity, which fell within the linear 206 portion of a standard curve. The concentrations were determined by linear regression 207 for the two dilutions and averaged to obtain the final SOD activity level. Biolabs, Ipswich, MA). Recommended reaction conditions were followed and PCR 220 products were purified using a QiaQuick PCR Purification Kit (Qiagen). The PCR 221 products were inserted into pCR2.1 TOPO vector using a TOPO TA Cloning Kit 222 (Invitrogen, Carlsbad, MA) and transformed using TOP10 cells. 10-20 colonies per 223 patient were picked for Miniprep cultures and plasmid DNA was subsequently extracted. 224 DERC Molecular Biology Core (Aurora, CO) sequenced plasmids containing the PCR 225 product using M13F-20 and M13R primers. Sequences were analyzed using CLC 226
Main Workbench software. 227 228 HDAC Activity: Class I, IIa and IIb HDAC activity was measured in lung tissue and 229 PASMC using a previously published protocol (27) . Briefly, the HDAC activity was 230 determined by incubating lung or cell extracts with specific synthetic HDAC substrates: 231 class I HDAC substrate (custom synthesis by Genscript, Piscataway, NJ), class IIa 232 HDAC substrate (I-1985) (Bachem, Torrance, CA), class I/IIb substrate (I-233 1875)(Bachem). The class specific HDAC substrates are based on ε-N-acylated lysine, 234 derivatized on the carboxyl group with 7-Amino-4-methylcoumarin (AMC)(Alfa Aesar). 235
Subsequent to deacylation by HDAC activity, samples were treated with trypsin to 236 release AMC, and the signal was detected as an increase in fluorescence using a 237
BioTek Synergy 2 plate reader, with excitation and emission 360 nm and 460 nm, 238 respectively, along with a 400 nm dichroic top mirror. Background signals were 239 subtracted from buffer blanks and data normalized to FD. 240
241
HAT activity: HAT activity was measured in PASMC nuclear extractions using an 242
EpiQuick HAT Activity/Inhibition Assay Kit (Epigentek). Data were expressed as 243 ng/min. 244
245
Chronically hypoxic rat model: RNA was isolated from lung tissue harvested from 246 rats exposed to 3 weeks of hypobaric hypoxia from a published study demonstrating 247 protection against chronic hypoxic pulmonary hypertension by daily intraperitoneal 248 injections of the HDAC inhibitor MGCD0103 (10 mg/kg in 50:50 DMSO:PEG-300) (4). 249
The animal experiments were conducted in accordance with the National Institute of 250 To increase the probability of observing a difference between FD and IPAH, we 282 selected 4 FD lungs with high SOD3 mRNA expression and 4 IPAH with low SOD3 283 mRNA expression. Following bisulfite conversion and DNA sequencing, we found that 284 the overall % methylation of the SOD3 promoter was not different in FD vs. IPAH, with 285 36.8% methylation in FD and 31.0% in IPAH (p>0.05)( Figure 4A ). Furthermore, there 286 was no difference at any of the 18 CpG sites between FD and IPAH (p>0.05), though 287 there was a difference in % methylation at particular CpG sites, ranging from 11% to 288 65% (p<0.001)( Figure 4B ). The % methylation of the SOD3 promoter in PASMC was 289 significantly lower than the % methylation observed in the lung samples. Furthermore, in 290 contrast to tumors, there was not an increase in DNA methylation in the IPAH PASMC 291 and, in fact, it was lower than the FD PASMC (7.9% ± 2.0 vs. 2.8% ± 0.6, 292 We then tested whether histone deacetylase activity contributed to low EC-SOD 308 mRNA expression in IPAH using a series of specific HDAC inhibitors. We evaluated the 309 SOD3 mRNA expression in PASMC from 5 different IPAH and FD subjects. One outlier 310 from each group with very high SOD3 content at baseline was excluded from analysis 311 (data not shown). There was an overall significant difference in SOD3 gene expression 312 in IPAH PASMC compared to FD and in response to HDAC inhibitors (p<0.001) (Figure  313 6A). Specifically, IPAH PASMC SOD3 mRNA expression increased following treatment 314 with the selective class I HDAC 1, 2 and 3 inhibitor MGCD0103; or class I HDAC 1 and 315 3 inhibitor MS275, with no significant response to the class I HDAC 1 and 2 inhibitor BA-316 60 or class IIb inhibitor TubA. There was also a trend towards an increase in SOD3 317 expression with the pan-HDAC inhibitor TSA in the IPAH cells ( Figure 6A ). Cell contribution of specific class I HDACs, we measured SOD3 expression after siRNA 334 knock down of class I HDAC1, 2 or 3 in human PASMC. In pilot experiments, we 335 observed that class I HDAC1 siRNA decreased HDAC1 protein at 48 and 72 hours, but 336 increased HDAC2 protein expression, with no change in SOD3 protein (data not 337 shown). Therefore, we tested each siRNA molecule 72 hours after transfection 338 individually and in combination to account for potential compensatory responses in 339 HDAC expression. Figure 7A -C shows the greater than 90% knock-down of class I 340 HDAC1, HDAC2 or HDAC3 mRNA at 72 hours with the respective siRNA molecule. 341 SOD3 mRNA expression after class I HDAC knock-down was highly variable and 342
showed a different response and time-course each time the experiment was repeated. 343
Overall, we could not demonstrate a consistent or significant change in SOD3 gene 344 expression after siRNA treatments at 48 or 72 hours (data not shown). SOD3 protein 345 expression, however, significantly increased 72 hours after knock-down of class I 346 HDAC3 siRNA, but not class I HDAC1 or HDAC2 siRNA ( Figure 7D ). We pooled the 347 protein expression data into three groups for analysis: 1) siHDAC1 alone; 2) siHDAC2 348 and siHDAC1&2; and 3) siHDAC3, siHDAC1&3 and siHDAC1,2&3. This approach best 349 demonstrates the increase in SOD3 expression whenever HDAC3 is included in the 350 pool of siRNA ( Figure 7E) . (49, 56). Therefore, we evaluate the nuclear expression of SP1 in PASMC nuclear 355 extracts and immunoprecipitated SP1 to evaluate for lysine acetylation. We observed 356 no difference in total nuclear SP1 expression between FD and IPAH ( Figure 8A ). We 357 did detect acetylation in immunoprecipitated SP1 from PASMC, though there was no 358 difference between FD and IPAH ( Figure 8B) . 359
Treatment of chronically hypoxic rats with the class I HDAC inhibitor MGCD0103 361 increased lung Sod3 mRNA expression. To further evaluate the role of histone 362 deacetylation on Sod3 mRNA expression, we examined the lungs of chronically hypoxic 363 rats treated with the HDAC inhibitor MGCD0103. We previously reported that treatment 364 with MGCD0103 protected against chronic hypoxic PH, including a 30% decrease in 365 pulmonary artery systolic pressures measured by right heart catheterization as well as 366 normalization of the PA acceleration time by echocardiography (4). We analyzed lung 367 tissue from these rats for SOD3 mRNA expression. We observed an increase in Sod3 368 mRNA expression in rats exposed to 3 weeks of hypoxia during HDAC inhibitor 369 treatment compared to normoxic or hypoxic rats (p<0.001) (Figure 9 ). 370 371 Discussion:
372
We utilized human lung tissue and PASMC obtained through the PHBI to test 373 whether SOD3 is decreased in IPAH lung due to DNA methylation or histone 374 deacetylation. We report a significant decrease in lung SOD3 gene expression and 375 enzyme activity in lung tissue from individuals with late stage IPAH at time of lung 376 transplantation compared to lungs from failed donors. Furthermore, SOD3 expression 377 in IPAH PASMC was regulated by class I HDAC3 activity. This conclusion was based 378 on our data showing selective class I HDAC inhibitors with activity against HDAC3 379 increased SOD3 gene expression and reduced the rate of cell proliferation in IPAH 380 PASMC. Furthermore, siRNA knock-down of class I HDAC3 but not HDAC1 or HDAC2, 381 increased SOD3 gene expression. Finally, SOD3 mRNA expression was increased in 382 the lungs of chronically hypoxic rats treated with MGCD0103, the selective class I 383 HDAC inhibitor with activity against HDAC3. These studies provide new insight in the 384 regulation of SOD3 in the pulmonary circulation and add to the accumulating literature 385 providing a rationale to test the therapeutic role of selective HDAC inhibitors for the 386 treatment of IPAH. 387
We focused our studies on SOD3 in IPAH due to its function as a major vascular 388 antioxidant enzyme, and the published evidence from our group and others implicating 389 a critical role for low SOD3 on disease pathogenesis in animal models of pulmonary 390 hypertension (1, 12, 19, 31, 33, 47, 51) . Furthermore, we performed in vitro with 391 PASMC because this is the primary cellular source of SOD3 in the vessel wall (33, 57) . 392
The observation that SOD3 gene expression is decreased in the lungs of individuals 393 with IPAH is consistent with an earlier report that SOD3 mRNA is decreased in the 394 bronchial tissue of individuals with IPAH (28). We found that the changes in SOD 395 expression and activity were selective for SOD3 isoform. This is in contrast to a 396 previous study that reported that SOD2 gene expression is decreased in the lungs of 3 397 individuals who died of IPAH or non-lung related conditions, and was consistent with the 398 loss in SOD2 in the fawn hooded rat model of PH (2). One major challenge in the study 399 of PAH in humans is the limited availability of human lung and cell culture samples. As 400 IPAH specimens are obtained either at lung transplantation, as in our study, or at the 401 time of autopsy, the data reflect the state in end-stage disease. Furthermore, the control 402 population is not uniform; in our study, the lungs provided by the PHBI tissue bank were 403 not accepted for lung transplantation therefore the reproducibility of the data from 404 control samples may have been confounded by the presence of underlying lung 405 diseases or acute lung injury that could impact SOD expression or activity. We 406 speculate that these factors contributed to the high variability in the outcome measures 407 including SOD3 expression, particularly in FD PASMC. In the face of these limitations, 408 the decrease in lung SOD3 gene expression in IPAH was notable, so we proceeded to 409 evaluate the role of DNA methylation and histone acetylation on the regulation of SOD3. 410
We first evaluated DNA hypermethylation of the SOD3 promoter because this 411 epigenetic mechanism is responsible for low SOD3 expression in lung, breast and 412 pancreatic cancers and contributes to enhanced tumor growth, survival, and invasion 413 (30, 34, 44, 45, 55) . In addition, DNA methylation of the SOD3 promoter contributes to 414 lower baseline SOD3 expression in normal human PAEC compared to PASMC (57). In 415 the study by Zelko et al, they report low levels (<10%) and advances in the development of new selective HDAC inhibitors (9, 10, 21, 26, 29, 42, 435 58) In animal studies, it is clear that HDAC inhibitors may not benefit every model of 436 PH, and a pan-HDAC inhibitor may even be harmful, both important points necessitating 437 a better understanding of this process in human disease (3,7). To date, there are few 438 human studies examining histone deacetylation in IPAH, and they are limited to testing 439 HDAC subtype expression, rather than activity (21, 23, 58 liver, kidney and lung fibroblasts, and histone deacetylation contributed to the low 453 expression of SOD3 in PAEC compare to PASMC (54, 57). They recently also showed 454 histone H3 and H4 acetylation in the SOD3 promoter region in PAEC, further implicating 455 histone acetylation in the normal low PAEC SOD3 expression. They also did not see an 456 increase in SOD3 in commercially available PASMC with two class I and II HDAC 457 inhibitors, scriptaid or HDAC-42, similar to our observation that control FD PASMC did 458 not significantly increase SOD3 expression in response to class I HDAC inhibitors, (53). 459
In a published study using neonatal ovine PASMC, class I HDAC inhibition with apicidin 460 increased SOD3 expression, providing further evidence that class I HDACs regulate 461 SOD3, and suggesting that there may be age or species-dependent variability (52). 462
Though we focused on class I HDACs, because of their recognized role in 463 cardiovascular diseases, there are also a number of recent though discrepant studies 464 examining sirtuins, in particular SIRT1 and SIRT3, in PH; the role of sirtuins warrant 465 future interrogation (5, 38, 50) . To the best of our knowledge, this is the first study to 466
show that class I HDAC3 activity regulates SOD3 expression. 467
468
Class I HDACs, including HDAC3, can associate with SP1 and SP3, ubiquitous 469 hypoxia-responsive transcription factors implicated in both repression and activation of 470 genes. (16, 20, 22, 24) . This has potential relevance in the regulation of SOD3 in IPAH, 471 particularly given the known role of SP1/ SP3 in the regulation of SOD3 gene 472 expression, and the impact of HDAC inhibitors on SOD3 expression. In addition to 473 modulating HDAC activity, SP1 is also a target of acetylation; acetylation of SP1 474 decreases its promoter binding affinity and can be reversed by HDAC inhibitors (16, 20, 475 22, 24, 49) . Our data confirms SP1 acetylation in PASMC, indicating that it may be a 476 mechanism involved in SOD3 expression. However we did not observe SP1 477 hyperacetylation in IPAH, suggesting that it did not appear to be responsible for the low 478 SOD3 expression in IPAH. The specific mechanism(s) by which HDACs regulate SOD3 479 in different cell types in IPAH or other forms of pulmonary hypertension will be an 480 important future direction. We propose that selective class I HDAC inhibitors may 481 protect not only by restoring normal PASMC SOD3 expression, but potentially by 482 increasing SOD3 in other cells including PAEC in which expression is repressed by 483 histone acetylation. 484
Though total HDAC activity, HAT activity and histone acetylation were similar 485 between FD and IPAH, there are a number of points to consider when interpreting these 486 data. A decrease in specific HDAC isoforms may not be reflected by the measurement 487 of total HDAC activity. Though the substrates are useful to differentiate different 488 classes, they are not specific for the different HDAC subtypes within a class. A similar 489 problem could contribute to the measures of histone acetylation, as site-specific 490 changes in histone acetylation may not be reflected by the total histone measurements. 491
This critical area of inquiry continues to require further investigation. 492
In conclusion, we provide new evidence that the lung expression and activity of the 493 key vascular antioxidant enzyme, SOD3, is selectively decreased in IPAH. In contrast to 494 a series of cancer studies, we did not find evidence that DNA hypermethylation was 495 responsible for the decrease in SOD3 expression. We provide strong evidence that 496 class I HDAC3 activity contributes to the impaired SOD3 expression and enhanced cell 497 proliferation in IPAH PASMC. Further studies are necessary to establish the 498 mechanisms responsible for cell-specific regulation of SOD3 in different forms of 499 pulmonary hypertension and determine if selective HDAC inhibitors can improve SOD3 500 activity, and contribute to their therapeutic efficacy to improve outcomes in this 501 devastating disease. 502
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